Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	68.23	74.68	58.84	44.58	39.84	10.18
Revenue Growth	56.18%	26.92%	32.00%	11.88%	291.46%	156.89%
Cost of Revenue	144.24	546.22	359.66	283.81	203.97	135.27
Gross Profit	-76.01	-471.54	-300.82	-239.24	-164.13	-125.09
Selling, General & Admin	148.3	176.59	178.18	110.82	81.6	57.68
Operating Expenses	424.93	176.59	178.18	110.82	81.6	57.68
Operating Income	-500.94	-648.13	-479	-350.06	-245.73	-182.78
Interest Expense	-	-1.81	-1.57	-0.1	-0.06	-2.95
Interest & Investment Income	6.26	22.79	15.76	19.12	6.25	0.07
Other Non Operating Income (Expenses)	8.5	-17.74	0.03	-1.09	0.05	0
EBT Excluding Unusual Items	-486.18	-644.9	-464.79	-332.13	-239.48	-185.65
Other Unusual Items	-	-	-	-	-	-0.83
Pretax Income	-480.23	-644.9	-464.79	-332.13	-239.48	-186.48
Income Tax Expense	-4.56	-0.14	-1.13	-4.06	-	-
Net Income	-475.67	-644.76	-463.66	-328.07	-239.48	-186.48
Net Income to Common	-475.67	-644.76	-463.66	-328.07	-239.48	-186.48
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	532	447	274	208	176	125
Shares Outstanding (Diluted)	532	447	274	208	176	125
Shares Change	32.62%	63.18%	31.92%	18.41%	40.04%	475.48%
EPS (Basic)	-0.89	-1.44	-1.69	-1.58	-1.36	-1.49
EPS (Diluted)	-0.89	-1.44	-1.69	-1.58	-1.36	-1.49
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-312.48	-378.28	-372.87	-299.74	-120.58	-198.41
Free Cash Flow Per Share	-0.59	-0.84	-1.36	-1.44	-0.69	-1.58
Operating Margin	-734.17%	-867.87%	-814.09%	-785.33%	-616.74%	-1795.79%
Profit Margin	-697.13%	-863.35%	-788.02%	-735.99%	-601.05%	-1832.18%
Free Cash Flow Margin	-457.97%	-506.52%	-633.71%	-672.43%	-302.64%	-1949.42%
EBITDA	-427.09	-564.43	-442.51	-325.66	-233.97	-174.37
D&A For EBITDA	73.85	83.7	36.49	24.4	11.76	8.41
EBIT	-500.94	-648.13	-479	-350.06	-245.73	-182.78
Revenue as Reported	68.23	74.68	58.84	44.58	39.84	10.18

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error